Viatris Confirms Delay On ‘First And Only’ Botox Biosimilar
Problems For Partner Revance’s Lead Pipeline Candidate Has ‘Direct Impact’
Executive Summary
Viatris remains hopeful of obtaining FDA approval for its proposed biosimilar to Botox in partnership with Revance Therapeutics in 2026, after the latter’s manufacturing problems for another drug candidate stymied development of the rival to the world-renowned cosmetic brand.
You may also be interested in...
Viatris’ Once-Monthly Copaxone Filing Imminent, Botox ‘On Track’
Fresh from offloading almost all its interests in biosimilars to Biocon, Viatris continues to develop several follow-on products, which it hopes will add $1bn to the company’s top line by the end of the decade.
Viatris Swats Away Concerns Over Divestment Valuations
Viatris remains committed to completing the sale of its global biosimilars unit to Biocon Biologics, while continuing efforts to generate up to $9bn in pre-tax proceeds by the end of 2023 from divestments.
Viatris Will Not Rule Out Symbicort In 2022 As Trial Looms
Facing down a key patent infringement trial beginning on 19 May, Viatris is continuing to eye an opportunity to launch its Breyna generic version of AstraZeneca’s Symbicort before patent expiry in 2023.